Oligonucleotidic therapeutics

Expert Opinion on Drug Discovery

Volumn 3, Issue 9, 2008, Pages 991-996

  Isaka, Yoshitaka ^a   Imai, Enyu ^a   Takahara, Shiro ^a   Rakugi, Hiromi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Antisense oligonucleotide; Aptamer; Decoy; DNAzyme; Ribozyme; SiRNA

Indexed keywords

ADALIMUMAB; AGRO 100; ALN RSV 01; ANTISENSE OLIGONUCLEOTIDE; APTAMER; ARC 1779; AVI 4126; BEVASIRANIB; EDIFOLIGIDE; EZN 2968; FOMIVIRSEN; HEPTAZYME; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISIS 301012; LOCKED NUCLEIC ACID; OBLIMERSEN; OLIGONUCLEOTIDE; PEGAPTANIB; PHOSPHORODIAMIDATE MORPHOLINO OLIGONUCLEOTIDE; PHOSPHOROTHIOIC ACID; PLACEBO; PRO 051; RANIBIZUMAB; RIBONUCLEASE H; RIBOZYME; RNA INDUCED SILENCING COMPLEX; RPI 4610; SIRNA 027; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTISENSE THERAPY; ANTIVIRAL ACTIVITY; ARTICLE; BLEEDING; BREAST ADENOCARCINOMA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG PROTEIN BINDING; DRUG TARGETING; DUCHENNE MUSCULAR DYSTROPHY; HUMAN; INFLAMMATION; LYMPHOMA; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN DEGRADATION; PROTEIN DNA BINDING; PROTEIN MODIFICATION; PROTEIN SYNTHESIS; PROTEIN VARIANT; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RETINA MACULA AGE RELATED DEGENERATION; RNA INTERFERENCE; RNA SPLICING; SUBRETINAL NEOVASCULARIZATION; VIRUS INFECTION; VIRUS REPLICATION;

EID: 52649122869     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.3.9.991     Document Type: Article

References (35)

1. Kastelein JJ, Wedel MK, Baker BF, et al. Potent reduction of apolipoprotein B and low-density lipoprotein of an antisense short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 2006;114(16):1729-35
2. Aartsma-Rus A, Janson AA, Kaman WE, et al. Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. Hum Mol Genet 2003;12(8):907-14
3. Van Deutekom JC, Janson AA, Ginjaar IB, et al. Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 2007;357(26):2677-86
4. Summerton J. Morpholino antisense oligomers: the case for an RNase H-independent structural type. Biochim Biophys Acta 1999;1489(1):141-58
5. Draper BW, Morcos PA, Kimmel CB. Inhibition of zebrafish fgf8 pre-mRNA splicing with morpholino oligos: a quantifiable method for gene knockdown. Genesis 2001;30(3):154-6
6. Corey DR, Abrams JM. Morpholino antisense oligonucleotides: tools for investigating vertebrate development [reviews]. Genome Biol 2001;2(5):1015
7. Devi GR, Beer TM, Corless CL, et al. In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors. Clin Cancer Res 2005;11(10):3930-8
8. Kipshidze N, Iversen P, Overlie P, et al. First human experience with local delivery of novel antisense AVI-4126 with Infiltrator catheter in de novo native and restenotic coronary arteries: 6-month clinical and angiographic follow-up from AVAIL study. Cardiovasc Revasc Med 2007;8(4):230-5
9. Jabs DA, Griffiths PD. Fomivirsen for the treatment of cytomegalovirus retinitis. Am J Ophthalmol 2002;133(4):552-6
10. O'Brien S, Moore JO, Boyd TE, et al. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 2007;25(9):1114-20
11. Tarhini AA, Kirkwood JM. Oblimersen in the treatment of metastatic melanoma. Future Oncol 2007;3(3):263-71
12. Elmen J, Lindow M, Schutz S, et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008;452(7189):896-9
13. Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998;391(6669):806-11
14. Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411(6836):494-8
15. Song E, Lee SK, Wang J, et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 2003;9(3):347-51
16. Available from: http://www.opko.com/clinic.asp
17. Shen J, Samul R, Silva RL, et al. Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther 2006;13(3):225-34
18. Devincenzo J, Cehelsky JE, Alvarez R, et al. Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res 2008;77(3):225-31
19. Perez-Ruiz M, Barroso-DelJesus A, Berzal-Herranz A. Specificity of the hairpin ribozyme. Sequence requirements surrounding the cleavage site. J Biol Chem 1999;274(41):293C76-80
20. Santoro SW, Joyce GF. A general purpose RNA-cleaving DNA enzyme. Proc Natl Acad Sci USA 1997;94:4262-6
21. Weng DE, Masci PA, Radka SF, et al. A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor recepror-1 for patients with refractory solid tumors. Mol Cancer Ther 2005;4(6):948-55
22. Usman N, Blatt LM. Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics. J Clin Invest 2000;106(10):1197-202
23. Isaka Y. DNAzymes as potential therapeutic molecules. Curr Opin Mol Ther 2007;9(2):132-6
24. Morishita R, Gibbons GH, Horiuchi M, et al. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci USA 1995;92(13):5855-9
25. Alexander JH, Hafley G, Harrington RA, et al. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA 2005;294(19):2446-54
26. McNamara JO, Andrechek ER, Wang Y, et al. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 2006;24(8):1005-15
27. Ng EW, Shima DT, Calias P, et al. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev 2006;5(2):123-32
28. Gilbert JC, DeFeo-Fraulini T, Hutabarat RM, et al. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation 2007;116(23):2678-86
29. Laber DA, Sharma VR, Bhupalam L, et al. Update on the first phase I study of AGRO100 in advaced Cancer. J Clin Oncol 2005;23:3064
30. Grimm D, Streetz KL, Jopling CL, et al. Fatality in mice due to oversaturation of cellular microRNA/shorr hairpin RNA pathways. Nature 2006;441(7092):537-41
31. Braasch DA, Paroo Z, Constantinescu A, et al. Biodistribution of phosphodiester and phosphorothioate siRNA. Bioorg Med Chem Lett 2004;14(5):1139-43
32. Rusckowski M, Qu T, Roskey A, Agrawal S. Biodistribution and metabolism of a mixed backbone oligonucleotide (GEM 231) following single and multiple dose administration in mice. Antisense Nucleic Acid Drug Dev 2000;10(5):333-45
33. Song E, Zhu P, Lee SK, et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 2005;23(6):709-17
34. Takabatake Y, Isaka Y, Mizui M, et al. Exploring RNA interference as a therapeutic strategy for renal disease. Gene Ther 2005;12(12):965-73
35. Takabatake Y, Isaka Y, Mizui M, et al. Chemically modified siRNA prolonged RNA interference in renal disease. Biochem Biophys Res Commun 2007;363(2):432-7